{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:07:59Z","timestamp":1791216479047,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The co-occurrence of myasthenia gravis (MG), inflammatory myopathy (IM), and fulminant myocarditis (FM) has rarely been reported. The few previous articles were mostly case reports or small sample data analysis, and the etiology was mostly attributed to thymoma and\/or the application of immune checkpoint inhibitors (ICIs). We report a 74-year-old woman with an acute onset of general weakness, chest tightness, shortness of breath, dysarthria, masticatory weakness and dysphagia, without myalgia or rash. Acetylcholine receptor antibody was positive. Serum creatine kinase, transaminase, and myoglobin were higher than normal. A variety of autoimmune antibodies including anti-Ro-52, JO-1, nRNP and dsDNA antibodies were positive. Chest CT showed no thymoma, bronchiectasis with infection in both lungs. Some of them showed interstitial changes. Electromyography repetitive nerve stimulation of the bilateral deltoid muscle demonstrated a decremental response at low frequencies without an incremental response at high frequencies. Needle electromyography revealed spontaneous potentials. Echocardiography showed that left ventricular wall motion was generally reduced, left ventricular systolic function was reduced, and cardiac function was EF18%. Muscle biopsy suggested myogenic injury. The patient was diagnosed with MG-IM-FM coexisting without thymoma and without ICIs. After treatment with Efgartigimod combined with intravenous methylprednisolone, the symptoms were relieved, serum creatine kinase, myoglobin and other laboratory indicators and cardiac function returned to normal. MG-IM-FM is a complex disease with rapid onset, rapid progression and critical condition. Clinicians should be on high alert and early intervention is the key to improve the prognosis. The immune mechanism of its occurrence is still unclear and needs to be further studied. Traditional glucocorticoid is still the first-line drug, but the new targeted drug Efgartigimod has less adverse reactions and faster onset of action, which may become a good choice, but needs to be verified by a larger sample.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1769065","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:40:20Z","timestamp":1775022020000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: Efgartigimod combined with intravenous methylprednisolone in a case of co-occurrence of unexplained myasthenia gravis, inflammatory myopathy, and fulminant myocarditis"],"prefix":"10.3389","volume":"17","author":[{"given":"Hongxia","family":"Yang","sequence":"first","affiliation":[{"name":"Center of Treatment of Myasthenia Gravis, Shijiazhuang People\u2019s Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulin","family":"Pan","sequence":"additional","affiliation":[{"name":"Center of Treatment of Myasthenia Gravis, Shijiazhuang People\u2019s Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[{"name":"Center of Treatment of Myasthenia Gravis, Shijiazhuang People\u2019s Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Center of Treatment of Myasthenia Gravis, Shijiazhuang People\u2019s Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biqi","family":"Cheng","sequence":"additional","affiliation":[{"name":"Center of Treatment of Myasthenia Gravis, Shijiazhuang People\u2019s Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyan","family":"Qi","sequence":"additional","affiliation":[{"name":"Center of Treatment of Myasthenia Gravis, Shijiazhuang People\u2019s Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"B1","article-title":"Myasthenia gravis and congenital myasthenic syndromes","volume":"195","author":"Gilhus","year":"2023","journal-title":"Handb Clin Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.790941","article-title":"Comorbid autoimmune diseases in patients with myasthenia gravis: A retrospective cross-sectional study of a chinese cohort","volume":"12","author":"Shi","year":"2021","journal-title":"Front Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06489-8","article-title":"Distal upper limb involvement in myasthenia-myositis association","volume":"44","author":"Lauletta","year":"2023","journal-title":"Neurol Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"102498","DOI":"10.1016\/j.autrev.2020.102498","article-title":"Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of Myasthenia-Myositis association from a large cohort of patients","volume":"19","author":"Garibaldi","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06846-1","article-title":"Myasthenia gravis-myositis association: is it an overlap myositis or a distinct entity","volume":"44","author":"Kim","year":"2023","journal-title":"Neurol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000535","article-title":"Inflammatory myopathy with myasthenia gravis: Thymoma association and polymyositis pathology","volume":"6","author":"Uchio","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/IMCRJ.S449525","article-title":"Lethal immune myocarditis and myasthenia gravis due to anti-PD-1 treatment for a bladder cancer patient: A case report and possible treatment inspiration","volume":"17","author":"Gao","year":"2024","journal-title":"Int Med Case Rep J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11485-1","article-title":"Anti-titin antibodies are associated with myocarditis in patients with myasthenia gravis","volume":"270","author":"Kim","year":"2023","journal-title":"J Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2343023","article-title":"Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study","volume":"24","author":"Yang","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v12.i26.5863","article-title":"Cardiac implications in myasthenia gravis","volume":"12","author":"Elmati","year":"2024","journal-title":"World J Clin cases"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1423547","article-title":"Case report: Multi-antibody-positive myasthenia gravis concomitant myositis associated with thymoma","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e8968","DOI":"10.1002\/ccr3.8968","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: A case report","volume":"12","author":"Basnet","year":"2024","journal-title":"Clin Case Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.05.004","article-title":"Concurrent inflammatory myopathy and myasthenia gravis with or without thymic pathology: A case series and literature review","volume":"48","author":"Huang","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"B14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.21037\/atm.2020.01.79","article-title":"Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma","volume":"8","author":"Xing","year":"2020","journal-title":"Ann Transl Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/diagnostics14161794","article-title":"Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: A systematic review","volume":"14","author":"Lipe","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1472845","article-title":"Efgartigimod treatment for generalized myasthenia gravis: a single-center case series of 16 patients","volume":"15","author":"Nomura","year":"2024","journal-title":"Front Neurol"},{"key":"B17","article-title":"Dermatomyositis associated with thymoma: A case report and literature review","volume":"174","author":"Yildirim","year":"2023","journal-title":"Clin Ter"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e2242","DOI":"10.1002\/brb3.2242","article-title":"A systematic review of myasthenia gravis complicated with myocarditis","volume":"11","author":"Cheng","year":"2021","journal-title":"Brain Behav"},{"key":"B19","doi-asserted-by":"publisher","first-page":"123440","DOI":"10.1016\/j.jns.2025.123440","article-title":"The mortality of myasthenia gravis with myocarditis: A single-center retrospective study","volume":"471","author":"Zhang","year":"2025","journal-title":"J Neurol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e72152","DOI":"10.7759\/cureus.72152","article-title":"No muscle left behind: cardiac arrest and myocarditis in a patient with idiopathic inflammatory myopathy","volume":"16","author":"Williams","year":"2024","journal-title":"Cureus"},{"key":"B21","volume-title":"The meta-analysis of risk factors of dermatomyositis or polymyositis associated cardiac involvements","author":"Hong-Zi","year":"2020"},{"key":"B22","article-title":"Mechanism of early transient aggravation after glucocorticoid impact treatment in patients with myasthenia gravis","volume":"42","author":"Wen-Ming","year":"2015","journal-title":"J Int Neurol Neurosurg"},{"key":"B23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12883-025-04063-1","article-title":"Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the neonatal intensive care unit","volume":"25","author":"Shi","year":"2025","journal-title":"BMC Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"17562864251314746","DOI":"10.1177\/17562864251314746","article-title":"Sequential administration of efgartigimod shortened the course of Guillain-Barr\u00e9 syndrome: a case series","volume":"18","author":"Chen","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11970-1","article-title":"Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome","volume":"271","author":"Di Stefano","year":"2024","journal-title":"J Neurol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1533167","article-title":"Short-term treatment of CIDP with efgartigimod: a case series in China","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s13023-024-03501-6","article-title":"Clinical efficacy of efgartigimod combined with intravenous methylprednisolone in the acute phase of neuromyelitis optica spectrum disorders","volume":"19","author":"Yang","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07460-5","article-title":"Efgartigimod as a novel FcRn inhibitor for autoimmune disease","volume":"45","author":"Yang","year":"2024","journal-title":"Neurol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12321-4","article-title":"Efgartigimod in the treatment of Guillain-Barr\u00e9 syndrome","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"B33","first-page":"10","article-title":"Chinese society of cardiology, chinese journal of cardiology editorial committee Chinese society of cardiology, chinese journal of cardiology editorial committee China guidelines for the diagnosis and treatment of adult fulminant myocarditis","volume":"52","year":"2024","journal-title":"Chin J Cardiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12293-5","article-title":"Real-World experience with efgartigimod in patients with myasthenia gravis","volume":"271","author":"Fuchs","year":"2024","journal-title":"J Neurol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/mus.28003","article-title":"Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events","volume":"69","author":"Singer","year":"2024","journal-title":"Muscle Nerve"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1769065\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:40:35Z","timestamp":1775022035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1769065\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2026.1769065"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1769065","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"1769065"}}